We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

PET, SPECT Infusion Enhancements Streamline Infusion Scheduling

By MedImaging International staff writers
Posted on 29 May 2012
Platforms have been developed for the controlled administration of molecular agents for single photon emission tomography (SPECT) as well as information technology (IT) enhancements to streamline positron emission tomography (PET) infusion scheduling.

Bayer Healthcare--Radiology & Interventional (Tarrytown, NY, USA) will present new device technologies at the annual meeting of the Society of Nuclear Medicine (SNM) in Miami (FL, USA), June 9-13, 2012. The new technology includes enhancements to the Intego PET infusion system, as well as developing platforms for controlled administration of molecular agents for SPECT and small animal imaging procedures.

In PET, the Medrad Intego system is a worldwide market leader and the only US Food and Drug Administration (FDA)-cleared system for administration of 18F-fluorodeoxyglucose (FDG) and 18F-sodium fluoride (NaF). Bayer has continued to advance and evolve the Intego platform since its launch in 2008, including adding software features, expanding compatibility and indications, and considerably reducing the size of the device. At SNM, Bayer plans to demonstrate Certegra informatics systems for Intego, including wireless integration to hospital information systems/radiology information systems/picture archiving and communication systems (HIS/RIS/PACS), which simplify downloading the PET modality worklist as an infusion schedule and sending infusion results to PACS. This new capability will replace several manual processes, which subsequently will streamline workflow and improve efficiency for PET imaging clinics.

Doug Descalzi, Bayer senior director of molecular devices, said, “Automated, controlled injection of molecular agents not only has safety and workflow benefits for staff, it can lead to improvements in patient care and help clinicians

Moreover, the company will present developing technologies for controlled administration of low energy radiopharmaceuticals and for small animal molecular imaging in a scientific exhibition.

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer, AG (Leverkusen, Germany, is one of the world’s leading companies in the healthcare and medical products industry. The company combines the global activities of the animal health, consumer care, medical care, and pharmaceuticals divisions.

Related Links:

Bayer Healthcare



New
Gold Member
X-Ray QA Meter
T3 AD Pro
Opaque X-Ray Mobile Lead Barrier
2594M
Silver Member
Radiographic Positioning Equipment
2-Step Multiview Positioning Platform
New
Portable Color Doppler Ultrasound System
S5000

Latest Nuclear Medicine News

AI Analysis of PET/CT Images Predicts Side Effects of Immunotherapy in Lung Cancer

New Imaging Agent to Drive Step-Change for Brain Cancer Imaging

Portable PET Scanner to Detect Earliest Stages of Alzheimer’s Disease